High Dose Thiotepa in Patients with Relapsed or Refractory Osteosarcomas: Experience of the SFCE Group

Introduction. Osteosarcoma relapse has a poor prognosis, with less than 25% survival at 5 years. We describe the experience of the French Society of Paediatric Oncology (SFCE) with high dose (HD) thiotepa and autologous stem cell transplantation (ASCT) in 45 children with relapsed osteosarcoma. Pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Marec-Berard, Perrine, Segura-Ferlay, Céline, Tabone, Marie-Dominique, Pacquement, Helene, Lervat, Cyril, Gentet, Jean-Claude, Schmitt, Claudine, Gaspar, Nathalie, Brugières, Laurence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3941142/
https://www.ncbi.nlm.nih.gov/pubmed/24672280
http://dx.doi.org/10.1155/2014/475067

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3941142/
https://www.ncbi.nlm.nih.gov/pubmed/24672280
http://dx.doi.org/10.1155/2014/475067

Ejemplares similares